Final interim results: Cosmo holds 94.773% of all BioXell Shares
(Thomson Reuters ONE) - bioXell S.p.A / Final interim results: Cosmo holds 94.773% of all BioXell Shares processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Milan, Italy,12 February 2010 - BioXell S.p.A. (SIX Swiss Exchange: BXLN) todayannounced the final interim results of the public tender offer of CosmoPharmaceuticals S.p.A. for the shares of BioXell S.p.A.. On 8 February 2010,which is the end of the offer period, Cosmo Pharmaceuticals S.p.A. holds(subject to the execution of the offer) 94.773 percent of the shares,respectively voting rights of BioXell S.p.A, Milano. The additional acceptanceperiod begins on 15 February 2010 and ends on 26 February 2010, 4.00 pm CET.Until the end of the offer period on 8 February 2010 4.00 pm CET, 5,100,300shares of BioXell S.p.A. (BioXell) with a par value of EUR 5 each ("BioXellShares") have been tendered under the public offer of 8 December 2009 of CosmoPharmaceuticals S.p.A. (Cosmo) made to the shareholders of BioXell ("Offer").This corresponds to 94.773 percent of all BioXell Shares, respectively of allshares, which the Offer refers to. Aside from the BioXell Shares tendered underthe Offer, Cosmo did not acquire any BioXell Shares or any other equitysecurities. Thus, as of the end of the offer period and subject to the executionof the Offer, Cosmo (including the persons acting in concert with Cosmo) holds atotal of 5,100,300 BioXell Shares corresponding to 94.773 percent of the sharesrespectively voting rights of BioXell.Condition a. in section B.11 of the Offer prospectus is met and Cosmo waives thefulfilment of condition b. in section B.11 of the Offer prospectus.Conditions c.to e. in Section B.11 of the Offer prospectus apply until the settlement of theOffer.The additional acceptance period for the acceptance of the Offer will start on15 February 2010 and end on 26 February 2010, 4.00 pm CET. During this periodall BioXell shareholders that have not yet accepted the Offer may tender theirshares. BioXell shareholders wishing to accept the Offer during the additionalacceptance period are asked to proceed according to the instructions of theircustodian bank. The Offer is subject to the Offer restrictions of the Offerprospectus. The offer consideration per BioXell share amounts to (i) CHF 2.8059in cash, (ii) 0.21044 shares in Cosmo, (iii) 0.21044 options to sell shares inCosmo (one option entitles to sell one share) to Cosmo at a price of CHF 21each, exercisable during the exercise period starting on 1 July 2011 and endingon 31 December 2011 (provided, however, that the put option shall lapse upon thesettlement of a public cash offer for all outstanding shares in Cosmo at anoffer price of CHF 21 or higher), and (iv) the possible supplement considerationdefined under section B.3.d) of the Offer prospectus.Subject to conditions c. to e. in section B.11 and a possible postponement ofthe execution of the Offer according to section B.11 of the Offer prospectus,the execution will probably take place until 12 March 2010.Cosmo announced that the ISIN of the put options for shares in Cosmo offered inthe context of the Offer as part of the offer consideration has been changed.The new ISIN of the Cosmo Put Options is IT0004576630. The security number andthe ticker symbol remain the same.All information on the tender Offer of Cosmo ncluding the Offer prospectus canbe viewed underwww.cosmopharmaceuticals.com.About BioXellBioXell S.p.A., a listed biopharmaceutical company focused on the discovery anddevelopment of drugs that exploit novel mechanisms of action, announced on 18November 2009 that it had entered into a transaction agreement with CosmoPharmaceuticals S.p.A. (SIX Swiss Exchange: COPN), headquartered in Lainate,Italy. After a comprehensive and careful review of all available strategicoptions and a thorough review of the terms of the proposed offer, BioXell'sBoard of Directors concluded unanimously that Cosmo's intended acquisition is inthe best interests of BioXell's shareholders.The detailed terms of the Offer were set out in Cosmo's offer prospectus on 8December 2009, which can be downloaded atwww.cosmopharmaceuticals.com
Unternehmensinformation / Kurzprofil:
Datum: 12.02.2010 - 07:00 Uhr
Sprache: Deutsch
News-ID 12386
Anzahl Zeichen: 0
contact information:
Town:
Milan
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 213 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Final interim results: Cosmo holds 94.773% of all BioXell Shares"
steht unter der journalistisch-redaktionellen Verantwortung von
bioXell S.p.A (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
